Hideki Kuki has been the President of Mitsubishi Tanabe Pharma Development America, Inc. since October 2016. With more than 20 years of experiences, he has held senior positions including General Manager of Project Management, Clinical Science, and Global Development Operations at our parent company, Mitsubishi Tanabe Pharma Corporation, in Japan and our group companies in Europe. He has successfully led Integrated Development Teams for canagliflozin (INVOKANA®/CANAGLU®) and other products, from the earliest development stage through NDA regulatory approval.
Vice President and Head of Regulatory Affairs
Doug Dobak brings extensive experience to our organization in regulatory affairs for pharmaceuticals and biologics in multiple therapeutic areas. He previously served as Global VP of Regulatory Affairs at Teva Pharmaceuticals Innovative Products. He also held senior management positions in Regulatory Affairs at NPS Pharmaceuticals, AstraZeneca, Astra Merck and Janssen Pharmaceutica.
Vice President and Head of Drug Safety
For more than 18 years, Ming has worked in clinical development and drug safety for pharmaceutical companies such as Wyeth, Amgen, TAP, and AbbVie. He has strong, diverse, global safety expertise and experience, encompassing Phase I trials, complete Life Cycle Management, and leadership of multiple product safety teams. Over the past two decades, Ming has published extensively in highly respected journals.
Head of Human Resources and General Affairs
In her role as Head of Human Resources (HR), Deborah Moorer oversees the strategic direction of all aspects of HR and is instrumental in shaping the company’s culture and employee development. She brings more than 20 years of HR experience to the role. Prior to joining Mitsubishi Tanabe Pharma Development America, Inc., she was Vice President of HR at Ipsen Biopharmaceuticals, Senior Vice President and HR Advisor at Citibank, and Vice President of HR at Alpharma.